| Literature DB >> 29333316 |
Teresa Paolucci1, Federico Zangrando1, Giulia Piccinini1, Laura Deidda2, Rossella Basile1, Enrico Bruno1, Emigen Buzi1, Alice Mannocci3, Franca Tirinelli4, Shalom Haggiag5, Ludovico Lispi5, Ciro Villani6, Vincenzo M Saraceni1.
Abstract
The aim of this study was to assess the efficacy of Mézières method in improving trunk flexibility of the back muscles and balance in patients with Parkinson's disease (PD). Materials and Methods. Thirty-six patients were randomized into 2 groups: the Mézières treatment group and the control group (home exercise group). The primary outcome was the improvement in balance per the Berg Balance Scale (BBS) and the trunk flexibility of the back for the anterior flexion trunk test. Also, we evaluated pain, gait balance for the Functional Gait Assessment (FGA), disease-related disability for the Modified Parkinson's Activity Scale and the Unified Parkinson's Disease Rating Scale (UPDRS), the quality of life, and the functional exercise capacity. All the measures were evaluated at baseline (T0), at the end of the rehabilitative program (T1), and at the 12-week follow-up (T2). Results. In the Mézières group, the BBS (p < .001) and trunk flexion test (p < .001) improved significantly at T1 and remained the same at T2. Between groups, significant changes were reported in FGA (p = .027) and UPDRS Total (p = .007) at T1 and in FGA (p = .03) at T2. Conclusion. The Mézières approach is efficacious in improving the flexibility of the trunk and balance in PD patients.Entities:
Year: 2017 PMID: 29333316 PMCID: PMC5733228 DOI: 10.1155/2017/2762987
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Figure 1Mézières rehabilitative method: (a) the first posture, (b) the second posture, (c) the third posture, and (d) variation of the third posture. Source of pictures: UOC Physical Medicine and Rehabilitation Unit, Policlinico Umberto I Hospital, Rome, Italy.
Figure 2CONSORT flow diagram.
Characteristics of the groups with regard to gender, age, and BMI (body mass index) at baseline (median and IQR, frequencies, and percentages).
| Characteristics | Control group | Mézières group | |||
|---|---|---|---|---|---|
|
|
| % |
| % |
|
| Gender | |||||
| Female | 8 | 47 | 7 | 41 | |
| Male | 9 | 53 | 10 | 59 | .95 |
|
| |||||
|
|
|
|
|
|
|
| Age | 67.00 | 11.00 | 66.00 | 18.50 | .65 |
| BMI | 25.00 | 5.50 | 25.80 | 2.90 | .99 |
IQR: interquartile range; BMI: body mass index.
Figure 3Functional Gait Assessment (FGA) at baseline (=T0) and at the end of treatment (=T1) and follow-up (=T2) for the two groups. The symbol “∗” indicates p < .05.
Figure 4Berg Balance Scale (BBS) at baseline (=T0) and at the end of the treatment (=T1) and follow-up (=T2) for the two groups.
Figure 5Modified Parkinson's Activity Scale (MPAS) at baseline (=T0) and at the end of the treatment (=T1) and follow-up (=T2) for the two groups.
Quality of life: comparison between groups at T1 (end of treatment) and T2 (follow-up) for SF-36 and subscales.
| SF-36 | Group B | Group A |
| Group B | Group A |
| ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |||
| PF | 75.00 | 35.00 | 75.00 | 15.00 | .40 | 85.00 | 45.00 | 85.00 | 25.00 | .90 |
| PR | 100.00 | 50.00 | 100.00 | 50.00 | .50 | 100.00 | 45.00 | 100.00 | 37.50 | .60 |
| BD | 61.00 | 31.00 | 62.00 | 30.00 | .20 | 61.00 | 50.00 | 72.00 | 43.50 | .20 |
| GH | 47.00 | 25.00 | 47.00 | 24.80 | .60 | 45.00 | 33.00 | 42.00 | 37.50 | .90 |
| VT | 50.00 | 15.00 | 57.50 | 15.00 | .10 | 50.00 | 23.00 | 55.00 | 27.50 | .50 |
| SF | 75.00 | 25.00 | 87.30 | 25.00 | .60 | 87.50 | 23.00 | 87.50 | 25.00 | .75 |
| RE | 66.70 | 34.00 | 100.00 | 33.80 | .20 | 100.00 | 50.00 | 100.00 | 33.40 | .40 |
| MH | 64.00 | 28.00 | 70.00 | 28.00 | .30 | 60.00 | 28.00 | 76.00 | 22.00 | .10 |
p value by Mann–Whitney test. Group A: Mézières treatment group; Group B: control group. IQR: interquartile range; SF-36: Short Form 36 Health Survey; PF: physical functioning; PR: physical role functioning; BD: bodily pain; GH: general health perceptions; VT: vitality; SF: social role functioning; RE: emotional role functioning; MH: mental health.
Scales and clinical evaluation: comparison between groups at T1 (end of treatment) and T2 (follow-up) for pain, mobility (balance and posture), and disability (median and IQR, p < .05).
| Scales and clinical evaluations | Group B | Group A |
| Group B | Group A |
| ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |||
| VAS (cm) | 2.50 | 4.00 | 2.00 | 4.00 | .20 | 3.00 | 4.00 | 1.50 | 4.00 | .80 |
|
| ||||||||||
| BBS | 50.00 | 8.00 | 54.50 | 8.00 | .10 | 50.00 | 5.00 | 51.50 | 7.50 | .28 |
|
| ||||||||||
| Trunk flexion test (cm) | 10,00 | 10.00 | 10.00 | 11.80 | .60 | 10.00 | 10.00 | 8.00 | 12.00 | .50 |
|
| ||||||||||
| FGA | 11.00 | 6.00 | 9.00 | 6.00 |
| 11.00 | 5.00 | 8.00 | 6.00 |
|
|
| ||||||||||
| MPAS | 40.00 | 10.00 | 47.00 | 13.50 | .30 | 40.00 | 10.00 | 47.00 | 14.00 | .11 |
|
| ||||||||||
| SMWT (min) | 500.00 | 145.00 | 510.00 | 171.30 | .90 | 500.00 | 130.00 | 480.00 | 277.50 | .80 |
|
| ||||||||||
| UPDRS Part I | 7.00 | 7.00 | 7.50 | 7.00 | .3 | 8.00 | 8.00 | 5.00 | 7.00 | .05 |
| UPDRS Part II | 7.00 | 6.00 | 6.00 | 5.80 | .40 | 6.00 | 8.00 | 6.00 | 5.50 | .90 |
| UPDRS Part III | 11.00 | 8.00 | 10.00 | 8.50 | .50 | 13.00 | 10.00 | 10.00 | 9.00 | .20 |
| UPDRS Part IV | 2.00 | 5.00 | 2.50 | 4.80 | .98 | 0.99 | 5.00 | 3.00 | 4.50 | .95 |
| UPDRS Total | 49.00 | 0.00 | 49.00 | 12.50 |
| 37.00 | 0.00 | 38.00 | 20.00 | .80 |
p value by Mann–Whitney test. Group A: Mézières treatment group; Group B: control group. IQR: interquartile range. VAS: Visual Analog Scale; BBS: Berg Balance Scale; FGA: Functional Gait Assessment; MPAS: Modified Parkinson's Activity Scale; SMWT: six-minute walking test; UPDRS: Unified Parkinson's Disease Rating Scale.
Scales and clinical evaluation: comparison for Mézières group at 3 evaluation times.
| Scales and clinical evaluations for Mézières group |
|
|
|
| WBb | Effect sizec | |||
|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | ||||
| VAS (cm) | 3.0 | 4.0 | 2.0 | 4.0 | 1.5 | 4.0 |
| 1; 2 | 0.24; 0.25 |
|
| |||||||||
| SF-36 PF | 72.5 | 33.8 | 75.0 | 15.0 | 85.0 | 25.0 | 0.014 | — | |
| SF-36 RP | 75.0 | 72.5 | 100.0 | 50.0 | 100.0 | 37.5 |
| 1 | 0.24 |
| SF-36 BP | 62.0 | 22.3 | 62.0 | 30.0 | 72.0 | 43.5 | 0.598 | — | |
| SF-36 GH | 42.0 | 29.0 | 47.0 | 25.0 | 42.0 | 37.5 | 0.198 | — | |
| SF-36 VT | 50.0 | 15.0 | 57.5 | 15.0 | 55.0 | 27.5 | 0.018 | — | |
| SF-36 SF | 75.0 | 34.8 | 87.3 | 25.0 | 87.5 | 25.0 |
| — | |
| SF-36 RE | 100.0 | 66.7 | 100.0 | 33.8 | 100.0 | 33.0 | 0.368 | — | |
|
| |||||||||
| BBS | 48.0 | 6.5 | 54.5 | 8.0 | 51.5 | 7.5 |
| 1; 2 | 0.25; 0.25 |
|
| |||||||||
| Trunk flexion test (cm) | 10.5 | 10.0 | 10.0 | 11.8 | 8.0 | 12.0 |
| 1; 2 | 0.24; 0.24 |
|
| |||||||||
| FGA | 15.0 | 5.0 | 9.0 | 6.0 | 8.0 | 6.0 |
| 1; 2 | 0.24; 0.24 |
|
| |||||||||
| MPAS | 37.0 | 16.0 | 47.0 | 13.5 | 47.0 | 14.0 |
| 1; 2 | 0.24; 0.24 |
|
| |||||||||
| SMWT (min) | 467.5 | 157.5 | 510.0 | 171.3 | 480.0 | 277.5 | 0.081 | — | |
|
| |||||||||
| UPDRS Part I | 10.0 | 9.0 | 7.5 | 7.0 | 5.0 | 7.0 |
| 1; 2 | 0.24; 0.24 |
| UPDRS Part II | 9.0 | 6.8 | 6.0 | 5.8 | 6.0 | 5.5 |
| 1; 2 | 0.24; 0.24 |
| UPDRS Part III | 15.5 | 10.8 | 10.0 | 8.5 | 10.0 | 9.0 |
| 1; 2 | 0.24; 0.24 |
| UPDRS Total | 38.0 | 20 | 27.0 | 12.5 | 23.0 | 16.5 |
| 1; 2 | 0.24; 0.24 |
Group A: Mézières treatment group; IQR: interquartile range; VAS: Visual Analog Scale; SF-36: Short Form 36 Health Survey; PF: physical functioning; PR: physical role functioning; BD: bodily pain; GH: general health perceptions; VT: vitality; SF: social role functioning; RE: emotional role functioning; MH: mental health; BBS: Berg Balance Scale; FGA: Functional Gait Assessment; MPAS: Modified Parkinson's Activity Scale; SMWT: six-minute walking test; UPDRS: Unified Parkinson's Disease Rating Scale. ap value obtained by Friedman test. bSignificant comparisons obtained by Wilcoxon test with Bonferroni correction (0.017 is the critical level of significance of Bonferroni correction, i.e., 0.05/3: 1 → T0 versus T1; 2 → T0 versus T2; 3 → T1 versus T2; not significant comparisons). cEffect size for the post hoc comparison. Bold font indicates statistical significance.
Scales and clinical evaluation: comparison for the control group at 3 evaluation times.
| Scales and clinical evaluations for the control group |
|
|
|
| WBb | Effect sizec | |||
|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | ||||
| VAS (cm) | 3.0 | 3.5 | 2.5 | 4.0 | 3.0 | 4.0 | 0.226 | — | |
|
| |||||||||
| SF36-PF | 75.0 | 45.0 | 75.0 | 35.0 | 85.0 | 45.0 | 0.108 | — | |
| SF36-RP | 50.0 | 75.0 | 100.0 | 50.00 | 100.0 | 45.0 | 0.054 | — | |
| SF-36 BP | 61.0 | 20.0 | 61.0 | 31.00 | 61.0 | 50.0 | 0.497 | — | |
| SF-36 GH | 42.0 | 13.0 | 47.0 | 25.00 | 45.0 | 33.0 | 0.627 | — | |
| SF-36 VT | 50.0 | 10.0 | 50.0 | 15.00 | 50.0 | 23.0 | 0.412 | — | |
| SF-36 SF | 75.0 | 38.0 | 75.0 | 25.00 | 87.5 | 23.3 | 0.575 | — | |
| SF-36 RE | 66.7 | 66.7 | 66.7 | 34.00 | 100.0 | 50.0 | 0.430 | — | |
| SF-36 MH | 68.0 | 16.0 | 64.0 | 28.00 | 60.0 | 28.0 | |||
|
| |||||||||
| BBS | 48.00 | 7.0 | 50.0 | 8.00 | 50.0 | 5.0 | 0.360 | — | |
|
| |||||||||
| Trunk flexion test (cm) | 11.00 | 10.0 | 10.0 | 10.00 | 10.0 | 10.0 | 0.012 | 1; 2 | 0.26; 0.26 |
|
| |||||||||
| FGA | 14.00 | 6.0 | 11.0 | 6.00 | 11.0 |
| 1; 2 | 0.26; 0.26 | |
|
| |||||||||
| MPAS | 37.00 | 13.0 | 40.0 | 10.00 | 40.0 | 10.0 |
| 1; 2 | 0.26; 0.26 |
|
| |||||||||
| SMWT (min) | 480.00 | 120.0 | 500.0 | 145.00 | 500.0 | 130.0 |
| 1 | 0.26 |
|
| |||||||||
| UPDRS Part I | 10.00 | 8.0 | 7.0 | 7.00 | 8.0 | 8.0 | 0.262 | — | |
| UPDRS Part II | 9.00 | 9.0 | 7.0 | 6.00 | 6.0 | 8.0 | 0.050 | — | |
| UPDRS Part III | 14.00 | 10.0 | 11.0 | 8.00 | 13.0 | 10.0 | 0.064 | — | |
| UPDRS Part IV | 4.00 | 6.0 | 2.0 | 5.00 | 0.9 | 5.0 |
| 1; 2 | 0.26; 0.26 |
| UPDRS Total | 44.00 | 0.0 | 49.0 | 0.00 | 37.0 | 0.0 |
| 2 | |
Group B: control group; IQR: interquartile range; SF-36: Short Form 36 Health Survey; PF: physical functioning; PR: physical role functioning; BD: bodily pain; GH: general health perceptions; VT: vitality; SF: social role functioning; RE: emotional role functioning; MH: mental health; VAS: Visual Analog Scale; BBS: Berg Balance Scale; FGA: Functional Gait Assessment; MPAS: Modified Parkinson's Activity Scale; SMWT: six-minute walking test; UPDRS: Unified Parkinson's Disease Rating Scale. ap value obtained by Friedman test. bSignificant comparisons obtained by Wilcoxon test with Bonferroni correction (0.017 is the critical level of significance of Bonferroni correction, i.e., 0.05/3: 1 → T0 versus T1; 2 → T0 versus T2; 3 → T1 versus T2; not significant comparisons). cEffect size for the post hoc comparison. Bold font indicates statistical significance.